Roche exercises oncology option under Recursion collaboration; triggers undisclosed fee

RECURSION PHARMACEUTICALS, INC.

Roche exercised Validated Small Molecule Option for a Small Molecule Validation Program in a single oncology area.
Option exercised on September 28, 2023; Roche to pay a Validated Small Molecule Option Fee per the agreement.
This is under the Collaboration and License Agreement between Recursion, Genentech Inc., and F. Hoffmann-La Roche Ltd dated December 5, 2021.
Fee amount not disclosed; option represents milestone in the existing partnership.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.